Crossmark

Neratinib resistance and cross-resistance to other HER2-targeted drugs due to increased activity of metabolism enzyme cytochrome P4503A4

Crossref DOI link: https://doi.org/10.1038/bjc.2016.445

Published Online: 2017-02-02

Published Print: 2017-02

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Breslin, Susan

Lowry, Michelle C

O'Driscoll, Lorraine
License Information

Text and Data Mining valid from 2017-02-01
More Information

Article History

Received: 28 July 2016

Revised: 4 December 2016

Accepted: 15 December 2016

First Online: 2 February 2017

Competing interests

: The authors declare no conflict of interest.